RETA | tickerfilter.com

Fundamental analysis

24%

Profitability 0%

Dept financing 25%

Liquidity 75%

Performance 35%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

0.51%

1 Month

59.45%

3 Months

58.81%

6 Months

238.05%

1 Year

366.16%

2 Year

33.90%

Key data

Stock price

$167.16

P/E Ratio

-15.52

DAY RANGE

N/A - N/A

EPS

-$9.66

52 WEEK RANGE

$18.47 - $167.59

52 WEEK CHANGE

$5.92

MARKET CAP

5.498 B

YIELD

N/A

SHARES OUTSTANDING

33.036 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

N/A

BETA

0.78

PUBLIC FLOAT

AVERAGE 10 VOLUME

$1,502,519

AVERAGE 30 VOLUME

$1,357,047

Company detail

CEO: J. Warren Huff
Region: US
Website: https://reatapharma.com/
Employees: 0
IPO year: -

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Preparation Manufacturing
Sector: Manufacturing

reata pharmaceuticals, inc. (nasdaq:reta) is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. reata’s two most advanced clinical candidates, bardoxolone methyl and omaveloxolone, target the important transcription factor nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation.

RETA - Reata Pharmaceuticals Inc - Class A